



Mucinous borderline ovarian tumors with *BRAF*^{V600E} mutation may have low risk for progression to invasive carcinomas

Kaori Ohnishi¹ · Kentaro Nakayama¹ · Masako Ishikawa¹ · Tomoka Ishibashi¹ · Hitomi Yamashita¹ · Kohei Nakamura¹ · Toshiko Minamoto¹ · Kouji Iida¹ · Sultana Razia¹ · Noriyoshi Ishikawa² · Satoru Kyo¹

Received: 8 October 2019 / Accepted: 4 June 2020 / Published online: 16 June 2020
© The Author(s) 2020

Abstract

Purpose Mucinous ovarian carcinomas (MOCs) are relatively rare. It has been proposed that a subset of mucinous cystadenomas (MCAs) may progress to mucinous borderline tumors (MBTs), and then to MOCs. *KRAS* is the predominantly mutated gene in MOC; however, other associated mutations and the mechanism underlying carcinogenesis in MOC remain unclear. Here, we assessed molecular genetic alterations in mucinous ovarian tumors and constructed mutation profiles.

Methods Using the Sanger sequencing method, we assessed genetic mutations (*KRAS*, *BRAF*, *TP53*, and *PIK3CA*) in 16 cases of MOC, 10 cases of MBT, and 12 cases of MCA.

Results Among MOC cases, the prevalence of G12D and G13D *KRAS* mutations was 43.8% (7/16). No MOC cases showed V600E *BRAF* and *TP53* mutations. Among MBT cases, the prevalence of G12D *KRAS* mutation was 20.0% (2/10), those of *TP53* and *PIK3CA* mutations were nil, and that of V600E *BRAF* mutation was 40% (4/10). None of the genetic mutations assessed were detected among MCA cases.

Conclusion These results suggest that MBT with V600E *BRAF* mutation may rarely progress to MOC, while MBT with G12D or G13D *KRAS* mutation may more commonly progress to MOC.

Keywords *BRAF* · *KRAS* · *TP53* · Mucinous ovarian tumor

Abbreviations

MOC Mucinous ovarian carcinoma
MBT Mucinous ovarian tumor
MCA Mucinous cystadenoma

Introduction

Ovarian cancer is the most lethal gynecological malignancy worldwide [1]; recently, its incidence has increased. A dualistic model has been proposed for epithelial ovarian cancer: low-grade disease (type I) develops in a stepwise manner from a benign cystadenoma to a borderline tumor, and then to a carcinoma, whereas high-grade disease (type

II) develops de novo from the distal fallopian tube epithelium [2]. Mucinous ovarian tumors can be classified as type I tumors and mucinous ovarian carcinoma (MOC), which is a rare tumor that represents 2–4% of cases of epithelial ovarian carcinoma [3–6]. MOC has a good prognosis if diagnosed at an early stage; however, its prognosis is poor at advanced stages as it tends to be chemoresistant, particularly to platinum drugs [7].

Borderline tumors constitute approximately 10–20% of all epithelial ovarian masses [8]. The most common epithelial borderline tumor in Japan is the mucinous type, while the serous type is the most common in Western countries [9–11]. Ovarian borderline tumors are non-invasive cancers, have a good prognosis, and rarely require systemic therapy.

The RAS-RAF-MEK-ERK-MAP kinase pathway is often implicated in carcinogenesis; particularly, *RAS* oncogenes are key factors in tumor development [12]. *BRAF* and *KRAS* mutations are components of the mitogen-activated protein kinase (MAPK) cascade and *KRAS* mutations are common in mucinous ovarian tumors and prevalent among 40–50% of MOC cases [7]. It has been reported that the rates of *KRAS* mutations in normal ovaries, benign mucinous ovarian

✉ Kentaro Nakayama
kn88@med.shimane-u.ac.jp

¹ Department of Obstetrics and Gynecology, Shimane University School of Medicine, Enyacho 89-1, Izumo, Shimane 6938501, Japan

² Department of Organ Pathology, Shimane University School of Medicine, Izumo 6938501, Japan

tumors, mucinous ovarian borderline tumors, and MOC are 0%, 57%, 90%, and 76%, respectively, suggesting that it may play a major role in the progression from benign tumors to carcinomas [13]. *KRAS* mutation leads to constitutive activation of the protein by increasing guanosine diphosphate/guanosine-5'-triphosphate exchange or by decreasing the guanosine triphosphatase activity of the protein, and thereby associates with constitutive activation of the epidermal growth factor receptor signaling pathway, and brings about increased cell proliferation [12, 14].

The three *RAF* genes (*ARAF*, *BRAF*, and *CRAF*) encode cytoplasmic serine/threonine kinases and are modulated by binding to RAS. *BRAF* mutations brings about ERK activation, which promotes the regulation of the G1/S transition of the cell cycle [12]. *BRAF* mutations were reported in a large proportion of cases of malignant melanoma [15], papillary thyroid cancer [16, 17], colon cancer [17, 18], and hairy cell leukemia [19] with poor outcomes. In contrast, they were reportedly associated with early-stage disease and improved outcomes in patients with low-grade serous ovarian cancer [20, 21]. Thus far, the role of *BRAF* mutations in mucinous ovarian carcinogenesis remains unclear. Additional mutations in mucinous tumors have been observed in *TP53* and *PIK3CA*; however, all these cases emanated from Europe, Australia, or the United States [22–28]. Thus, the carcinogenesis of mucinous ovarian tumor among Japanese patients is still poorly understood. In the present study, we retrospectively investigated the mutation patterns of *BRAF*, *KRAS*, *PIK3CA*, and *TP53* in mucinous cystadenomas (MCAs), mucinous borderline tumors (MBTs), and MOC to clarify the role of each gene in mucinous ovarian carcinogenesis.

Materials and methods

Tumor samples

Formalin-fixed, paraffin-embedded tissue samples of 16 MOC, 10 MBT, and 12 MCA patients were used in this study. The samples were retrieved from the Department of Obstetrics and Gynecology, Shimane University Hospital (Izumo, Japan), which have collected from 2008 to 2017. The diagnoses were made based on conventional histopathologic examination of sections stained with hematoxylin and eosin. The tumors were categorized according to the World Health Organization subtype criteria by several pathologists in the Department of Pathology in Shimane University Hospital (Izumo, Japan). The tumors were staged according to the International Federation of Gynecology and Obstetrics classification system. All patients were primarily treated via surgery (i.e., total abdominal hysterectomy, bilateral salpingo-oophorectomy, and omentectomy) with or without pelvic and para-aortic lymph node dissection and adjuvant

taxane/platinum combination chemotherapy. The resected specimens of each case were reviewed by a gynecological pathologist (N.I.) and a gynecologic oncologist (K.N.). The protocol for the acquisition of tissue specimens and clinical information was approved by the institutional review board of Shimane University Hospital (Approval No. 2004–0381). All participants provided written informed consent. The study was conducted in accordance with the tenets of the Declaration of Helsinki and Title 45 (United States Code of Federal Regulations), Part 46 (Protection of Human Subjects), effective December 13, 2001.

Microdissection and DNA extraction

Sixteen MOC, 10 MBT, and 12 MCA cases had sufficient tumor tissue for DNA extraction and sequence analysis. Tissue sections which were reviewed and marked with lines by a skillful gynecological pathologist were placed on membrane slides and counterstained with hematoxylin. Selected tumor tissues on 10-mm sections were dissected under a microscope using a 24-gauge needle to obtain a high percentage of tumor cells. After 48 h of digestion with a proteinase, DNA was extracted from the microdissected samples using a QIAmp DNA Micro Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. We have confirmed carcinoma/stroma ratio is more than 50% of each sample.

Direct sequence analysis

Polymerase chain reaction amplification was performed on exon two of *KRAS*, exon 15 of *BRAF*, exons 4–9 of *TP53*, and exons 9 and 20 of *PIK3CA*, using genomic DNA obtained from microdissected formalin-fixed, paraffin-embedded tissue using the following primers: forward 5'-TTAACCTTATGTGTGACATGTTCTAA-3', reverse 5'-AGAATGGTCCTGCACCAGTAA-3' for exon two of *KRAS*; forward 5'-TGCTTGCTCTGATAGGAAAATG-3', reverse 5'-AGCATCTCAGGGCCAAAAT-3' for exon 15 of *BRAF*; forward 5'-CCTGGTCCTCTGACTGCTCT-3', reverse 5'-GCCAGGCATTGAAGTCTCAT-3' for exon 4 of *TP53*; forward 5'-TCAGATAGCGATGGTGAGCA-3', reverse 5'-CTTAACCCCTCCTCCCAGAG-3' for exon five of *TP53*; forward 5'-TCTGTCTCCTTCCTTCTTCTACA-3', reverse 5'-AACCAGCCCTGTCGTCTCT-3' for exon 6 of *TP53*; forward 5'-CTTGGGCTGTGTTATCTCC-3', reverse 5'-GGGTCAGAGGCAAGCAGA-3' for exon seven of *TP53*; forward 5'-GGGAGTAGATGGAGCCTGGT-3', reverse 5'-GCTTCTTGCTGCTTGCTT-3' for exon 8 of *TP53*; forward 5'-GGAGACCAAGGGTGCAGTTA-3', reverse 5'-CCCAATTGCAGGTAAAACA-3' for exon nine of *TP53*; forward 5'-GGAAAATATGACAAAGAAAGC-3', reverse 5'-CTGAGATCAGCCAAATTCAGTT-3' for

exon nine of *PIK3CA*; and forward 5'-CTCAATGATGCT TGGCTCTG-3', reverse 5'-TGGAATCCAGAGTGAGCT TTC-3' for exon 20 of *PIK3CA*. All polymerase chain reaction-amplified products were sequenced at Beckman Coulter (Danvers, MA, USA) and analyzed with the Mutation Surveyor DNA Variant Analysis Software (Tokyo, Japan).

Statistical analysis

All results are expressed as means \pm standard deviations. In some cases, the three groups were compared using the chi-square test and the Tukey–Kramer test, as appropriate. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Japan). All differences in analysis items were considered significant at $p < 0.05$.

Results

To assess the mutation profiles of mucinous tumors of the ovary, we performed direct sequence analysis on 38 tumor specimens, including 16 MOCs, 10 MBTs, and 12 MCAs. The clinical characteristics of the patients are summarized

in (Table 1). The mean ages of the patients at diagnosis were 59.6 ± 16.3 years for MOC, 56.5 ± 20.0 years for MBT, and 58.0 ± 18.2 years for MCA. There were no significant differences in the characteristics of the participants, cancer antigen (CA) 125 level, and CA19-9 level. A majority of the patients (81.3%) with MOC were found to have early stage I or II disease at diagnosis, and only 18.8% presented with advanced stage III or IV disease. Figure 1 shows representative examples of the histological appearance of mucinous ovarian tumors. Figure 2 shows typical point mutations in *KRAS* and *BRAF*.

All 38 cases were assessed for mutations in the *KRAS*, *BRAF*, *TP53*, and *PIK3CA* genes. *KRAS* mutations were detected in 7 of the 16 (43.8%) MOC cases and in 2 of the 10 (20%) MBT cases (Table 2). However, no *KRAS* mutations were detected in MCA cases. *KRAS* mutations tended to occur more frequently in MBT than in MCA ($p = 0.066$, Chi square test). *BRAF* mutations in exon 15 were only detected in four of the MBT cases, but not in the MOC or MCA cases. None of the mucinous tumor specimens showed *TP53* mutations. *BRAF* mutations occurred significantly more frequently in MBT cases than in MOC cases ($*p = 0.042$, Chi square test) (Table 3). *PIK3CA* mutation was detected in only one case of MCA.

Table 1 The number of each mucinous tumors

Histological diagnosis	Carcinoma	Borderline tumor	Cystadenoma	<i>P</i> value
Total No. of cases	16	10	12	
Age	59.6 ± 16.3 (25–81)	56.5 ± 20.0 (18–84)	58.0 ± 18.2 (26–80)	
Stage				
I	11	10		
II	2	0		
III	2	0		
IV	1	0		
Early stage (stage I, II)	81.3%			
Advanced stage (stage III, IV)	18.8%			
Grade				
I	8			
II	6			
III	2			
CA125 (U/ml)	121.2 ± 140.2 (8–458)	28.0 ± 20.0 (7–62)	81.9 ± 211.9 (6–749)	0.285* 0.773† 0.681‡
CA19-9 (U/ml)	1913.7 ± 6337.8 (1–24,780)	44.0 ± 56.5 (6–200)	70.2 ± 159.0 (8.3–546)	0.514* 0.504† 0.999‡

*Carcinoma vs. borderline tumor

†Carcinoma vs. cystadenoma,

‡Borderline tumor vs. cystadenoma (Tukey–Kramer test)




Fig. 1 Histological appearance of the mucinous ovarian tumors. (a) Hematoxylin and eosin (H&E) staining showing mucinous cystadenoma, (b) H&E staining showing mucinous borderline tumor, and (c) H&E staining showing mucinous ovarian carcinoma

Discussion


In the present study, we performed direct sequence analysis on 38 tumors, including 16 MOC, 10 MBT, and 12 MCA specimens to elucidate the genetic profile of mucinous

tumors of the ovary. Interestingly, *BRAF* mutations were more common in MBT than in MOC. However, *KRAS* mutations occurred with high frequency in MOC but with low frequency in MBT. No mutations were detected in the analyzed genes of MCA. These findings indicated that, in the disease continuum from MBT to MOC, the *BRAF* mutation in MBT may not result in progression to MOC, while *KRAS* mutations in MBT may be associated with progression to MOC (Fig. 3).

BRAF is a meaningful serine/threonine kinase that is an element of the RAS-RAF-MEK-ERK signaling pathway and plays a key role in cell proliferation and apoptosis. The complexity of this pathway is increased due to the multiplicity of its components. There are three *RAS* (*HRAS*, *NRAS*, and *KRAS*), three *RAF* (*ARAF*, *BRAF*, and *CRAF*), two *MEK* (*MEK1* and *MEK2*), and two *ERK* (*ERK1* and *ERK2*) genes. They encode proteins and do not have redundant functions [29]. *BRAF* binds to *CRAF* and activates its transphosphorylation, thereby regulating the pathway subtly [29].

The V600E *BRAF* mutation constitutes over 90% of all *BRAF* mutations in melanoma [29]. It has been found to activate the MAPK pathway by activating mutations of either *NRAS* or *BRAF* in most melanomas [30]. The *BRAF* and *CRAF* protein kinases are the most critical mediators of activated *RAS* [31]. For mutated *NRAS*, *CRAF* seems to be important in the downstream activation of MAPKs [32, 33]. *RAF* interacts with *MEK* and phosphorylates it, thereby activating *ERK* [31, 34, 35]. Activated *ERK* promotes the signal, through altered transcription of several genes [36]. *BRAF* mutations are observed in most melanocytic nevi (70–80%), metastatic melanomas (40–50%), and vertical growth phase melanomas (40–50%) [37–39], and might be an acquired event in early invasive melanoma that induces clonal expansion and tumor progression [36]. Consequently, *BRAF* mutation is associated with poor prognosis in not only melanoma but also papillary thyroid cancer and metastatic colon cancer [15–18]. In contrast, *BRAF* mutations were present in MBT but not in MOC in this study, suggesting that *BRAF* mutations are associated with the indolent type of MBT. Wong et al. reported that *BRAF* mutations are infrequent in advanced-stage low-grade serous ovarian carcinomas and could be improved prognostic markers [20]. Grisham et al. demonstrated that the presence of *BRAF* mutations in serous borderline ovarian tumor or low-grade serous ovarian carcinoma was relevant to early-stage disease and favorable prognoses [21]. Recently, it has been reported that lack of *Cdkn2a* in V600E *BRAF* mutated melanocytes in rodents is associated with rare progression to melanoma [40]. In MOC, *Cdkn2a/b* homozygous deletions/mutations were detected at high frequencies [41]. From these reports, it appears that loss of *Cdkn2a* in mucinous ovarian tumors with V600E *BRAF* mutation impairs progression to carcinoma. Therefore, *BRAF* mutation is associated with

Fig. 2 Chromatograms of *KRAS* and *BRAF* mutation statuses in representative ovarian tumors showing (a) a point mutation in the *KRAS* gene and (b) a point mutation in the *BRAF* gene



early-stage disease, such as MBT, and was not detected in MOC in the present study.

KRAS is the predominant mutated gene in MOC and may be related to the progression from benign to malignant tumors [7]. It has been reported that CRAF is a best target for carcinoma with *KRAS* mutations and intensifies MAPK signaling [42, 43]. Our results are consistent with those of previous studies regarding *KRAS*; the prevalences of *KRAS* mutations were 0%, 20%, and 43% among MCA, MBT, and MOC specimens, respectively. We also found that some cases had both *KRAS* and *BRAF* mutations in MBT. These MBT cases with both *KRAS* and *BRAF* mutations might progress to MOC earlier than would those without these mutations.

Recently, it has been reported that *TP53* mutations were key drivers of progression from MBT to MOC [44].

Surprisingly, in the present study, this mutation was not detected in all mucinous ovarian tumors. This discrepancy may have occurred because we investigated only mucinous ovarian tumor specimens obtained from Japanese patients. The carcinogenesis of MOC may be affected by ethnic genetic background. On the other hand, PCR amplification was not performed on exon 2, 3, 10 and 11. There is a possibility that *TP53* mutations could be detected in these exons. Additionally, some MOC cases are high-grade features and they may have *TP53* mutations without exon 4–9.

Our study indicates that *BRAF* and *KRAS* mutations are useful as prognostic biomarkers in MBT patients undergoing surgery. Single *BRAF* mutations in MBT may predict a favorable outcome. However, the patients with *KRAS* mutations might progress to MOC and require careful long-term follow-up.

Table 2 Genetic alterations in mucinous ovarian tumors

No	Hystotype	<i>KRAS</i>	<i>BRAF</i>	<i>TP53</i>	<i>PIK3CA</i>
1	Carcinoma	WT	WT	WT	WT
2	Carcinoma	G13D	WT	WT	E545K
3	Carcinoma	G13D	WT	WT	WT
4	Carcinoma	WT	WT	WT	WT
5	Carcinoma	WT	WT	WT	WT
6	Carcinoma	WT	WT	WT	WT
7	Carcinoma	WT	WT	WT	WT
8	Carcinoma	WT	WT	WT	WT
9	Carcinoma	G12D	WT	WT	WT
10	Carcinoma	WT	WT	WT	WT
11	Carcinoma	WT	WT	WT	WT
12	Carcinoma	G12D	WT	WT	WT
13	Carcinoma	WT	WT	WT	WT
14	Carcinoma	G12D	WT	WT	WT
15	Carcinoma	G13D	WT	WT	WT
16	Carcinoma	G12D	WT	WT	WT
17	Borderline tumor	WT	V600E	WT	WT
18	Borderline tumor	WT	WT	WT	WT
19	Borderline tumor	WT	WT	WT	WT
20	Borderline tumor	G12D	V600E	WT	WT
21	Borderline tumor	WT	WT	WT	WT
22	Borderline tumor	WT	V600E	WT	WT
23	Borderline tumor	WT	WT	WT	WT
24	Borderline tumor	G12D	V600E	WT	WT
25	Borderline tumor	WT	WT	WT	WT
26	Borderline tumor	WT	WT	WT	WT
27	Cystadenoma	WT	WT	WT	WT
28	Cystadenoma	WT	WT	WT	WT
29	Cystadenoma	WT	WT	WT	WT
30	Cystadenoma	WT	WT	WT	WT
31	Cystadenoma	WT	WT	WT	WT
32	Cystadenoma	WT	WT	WT	WT
33	Cystadenoma	WT	WT	WT	WT
34	Cystadenoma	WT	WT	WT	WT
35	Cystadenoma	WT	WT	WT	WT
36	Cystadenoma	WT	WT	WT	WT
37	Cystadenoma	WT	WT	WT	WT
38	Cystadenoma	WT	WT	WT	WT

Table 3 Frequency of *KRAS* and *BRAF* mutations in mucinous tumors

	<i>KRAS</i> (G12D or G13D)		<i>BRAF</i> (V600E)	
		<i>P</i> value		<i>P</i> value
PPCarcinoma	7/16 (43.8%)	> 0.05*	0/16 (0%)	0.042*
Borderline tumor	2/10 (20%)	0.066†	4/10 (40%)	> 0.05†
Cystadenoma	0/12 (0%)	> 0.05‡	0/12 (0%)	> 0.05‡

*Carcinoma vs. Borderline tumor


†Carcinoma vs. Cystadenoma

‡Borderline tumor vs. Cystadenoma (Chi square test)

The present study has several limitations. First, the number of samples in this study is small. This study is ongoing and the number of samples will increase. This will enable us to investigate statistically the relationship between the mutations identified in the present study and patient outcomes. Second, we did not search for loss or mutation of *Cdkn2a* in the present study. In addition, we also need to study *CRAF* mutations in mucinous ovarian tumors. Last, we assessed genetic mutations via Sanger sequencing; therefore, the kinds of gene mutations assessed were limited. Further experimentation with next generation sequencing is necessary to determine details of the molecular mechanism underlying mucinous ovarian carcinogenesis.

In summary, V600E *BRAF* mutations were detected only in MBT, while G12D/G13D *KRAS* mutations were detected more commonly in MOC than in MBT. We posit that MBT with V600E *BRAF* mutation may not progress to MOC and predict a favorable outcome, while MBT with G12D/G13D *KRAS* mutation may progress to MOC in the future.

Fig. 3 Possible carcinogenic process in mucinous ovarian tumors. Mucinous borderline tumor with *BRAF* mutation may not progress, while mucinous borderline tumor with *KRAS* mutation may progress to invasive carcinoma



Author contributions KO and KN drafted the manuscript. KO, TI, MI, KN, TM, HY, KI, NI, and RS carried out the molecular genetic studies. KO carried out the statistical analyses. KN participated in the design of the study. SK conceived of the study, participated in its design and coordination, and helped in drafting the manuscript. All authors have read and approved the final manuscript.

Funding This work was supported by JSPS KAKENHI grant numbers 18K09229 and 18K09291.

Compliance with ethical standards

Conflict of interest The authors declare no potential conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Siegel RL, Miller KD (2019) Cancer statistics. *CA Cancer J Clin* 69(1):7–34. <https://doi.org/10.3322/caac.21551>
- Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. *Am J Pathol* 164(5):1511–1518
- Gilks CB (2004) Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. *Int J Gynecol Pathol* 23(3):200–205
- Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. *Hum Pathol* 42(7):918–931. <https://doi.org/10.1016/j.humpath.2011.03.003>
- Tabrizi AD, Kalloger SE, Kobel M, Cipollone J, Roskelley CD, Mehl E, Gilks CB (2010) Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. *Int J Gynecol Pathol* 29(2):99–107. <https://doi.org/10.1097/PGP.0b013e3181bbbcc1>
- Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. *Int J Gynecol Pathol* 23(1):41–44. <https://doi.org/10.1097/01.pgp.0000101080.35393.16>
- Ricci F, Affatato R, Carrassa L, Damia G (2018) Recent insights into mucinous ovarian carcinoma. *Int J Mol Sci* 19:6. <https://doi.org/10.3390/ijms19061569>
- Vang R, Shih Ie M, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. *Adv Anat Pathol* 16(5):267–282. <https://doi.org/10.1097/PAP.0b013e3181b4fffa>
- Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S, Nanbu K, Matsushita K, Fukumoto M, Yamabe H, Mori T (1998) Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. *Hum Pathol* 29(1):34–40
- Takeshima Y, Amatya VJ, Daimaru Y, Nakayori F, Nakano T, Inai K (2001) Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection. *Hum Pathol* 32(11):1203–1208. <https://doi.org/10.1053/hupa.2001.28956>
- Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. *Cancer Res* 53(7):1489–1492
- Mayr D, Hirschmann A, Lohrs U, Diebold J (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. *Gynecol Oncol* 103(3):883–887. <https://doi.org/10.1016/j.ygyno.2006.05.029>
- Lee YJ, Lee MY, Ruan A, Chen CK, Liu HP, Wang CJ, Chao WR, Han CP (2016) Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. *Oncotarget* 7(50):82097–82103. <https://doi.org/10.18632/oncotarget.13449>
- Fabjani G, Kriegshaeuser G, Schuetz A, Prix L, Zeillinger R (2005) Biochip for K-ras mutation screening in ovarian

- cancer. *Clin Chem* 51(4):784–787. <https://doi.org/10.1373/clinchem.2004.041194>
15. Dhomen N, Reis-Filho JS, da Rocha DS, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. *Cancer Cell* 15(4):294–303. <https://doi.org/10.1016/j.ccr.2009.02.022>
 16. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. *Endocr Rev* 28(7):742–762. <https://doi.org/10.1210/er.2007-0007>
 17. Dvorak K, Aggeler B, Palting J, McKelvie P, Ruzkiewicz A, Waring P (2014) Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. *Pathology* 46(6):509–517. <https://doi.org/10.1097/PAT.000000000000119>
 18. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouche O, Taberner J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA (2017) Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. *J Natl Cancer Inst* 109:5. <https://doi.org/10.1093/jnci/djw272>
 19. Kreitman RJ (2019) Hairy cell leukemia: present and future directions. *Leuk Lymphoma* 1:11. <https://doi.org/10.1080/10428194.2019.1608536>
 20. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM (2010) BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. *Am J Pathol* 177(4):1611–1617. <https://doi.org/10.2353/ajpat.h.2010.100212>
 21. Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB (2013) BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. *Cancer* 119(3):548–554. <https://doi.org/10.1002/ncr.27782>
 22. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. *Cancer* 79(8):1581–1586
 23. Hunter SM, Goringe KL, Christie M, Rowley SM, Bowtell DD (2012) Australian Ovarian Cancer Study G, Campbell IG Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. *Clin Cancer Res* 18(19):5267–5277. <https://doi.org/10.1158/1078-0432.CCR-12-1103>
 24. Ryland GL, Hunter SM, Doyle MA, Rowley SM, Christie M, Allan PE, Bowtell DD (2013) Australian Ovarian Cancer Study G, Goringe KL, Campbell IG RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. *J Pathol*. 229(3):469–476. <https://doi.org/10.1002/path.4134>
 25. Wang Y, Helland A, Holm R, Kristensen GB, Borresen-Dale AL (2005) PIK3CA mutations in advanced ovarian carcinomas. *Hum Mutat* 25(3):322. <https://doi.org/10.1002/humu.9316>
 26. Mackenzie R, Kommos S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakum-Gamez J, McAlpine JN, Anglesio MS (2015) Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. *BMC Cancer* 15:415. <https://doi.org/10.1186/s12885-015-1421-8>
 27. Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD (2015) Australian Ovarian Cancer Study G, Campbell IG, Goringe KL Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. *Genome Med* 7(1):87. <https://doi.org/10.1186/s13073-015-0210-y>
 28. Vereczkey I, Serester O, Dobos J, Gallai M, Szakacs O, Szentirmai Z, Toth E (2011) Molecular characterization of 103 ovarian serous and mucinous tumors. *Pathol Oncol Res* 17(3):551–559. <https://doi.org/10.1007/s12253-010-9345-8>
 29. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 140(2):209–221. <https://doi.org/10.1016/j.cell.2009.12.040>
 30. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. *Clin Cancer Res* 9(17):6483–6488
 31. Beeram M, Patnaik A, Rowinsky EK (2005) Raf: a strategic target for therapeutic development against cancer. *J Clin Oncol* 23(27):6771–6790. <https://doi.org/10.1200/JCO.2005.08.036>
 32. Marquette A, Andre J, Bagot M, Bensussan A, Dumaz N (2011) ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. *Nat Struct Mol Biol* 18(5):584–591. <https://doi.org/10.1038/nsmb.2022>
 33. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, Marais R (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. *Cancer Res* 66(19):9483–9491. <https://doi.org/10.1158/0008-5472.CAN-05-4227>
 34. Garnett MJ, Rana S, Paterson H, Barford D, Marais R (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. *Mol Cell* 20(6):963–969. <https://doi.org/10.1016/j.molcel.2005.10.022>
 35. Terai K, Matsuda M (2006) The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. *EMBO J* 25(15):3556–3564. <https://doi.org/10.1038/sj.emboj.7601241>
 36. Sullivan RJ, Flaherty K (2013) MAP kinase signaling and inhibition in melanoma. *Oncogene* 32(19):2373–2379. <https://doi.org/10.1038/onc.2012.345>
 37. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. *Nature* 417(6892):949–954. <https://doi.org/10.1038/nature00766>
 38. Pollock PM, Harper UL, Hansen KS, Yudit LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. *Nat Genet* 33(1):19–20. <https://doi.org/10.1038/ng1054>
 39. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA (2003) BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. *Cancer Res* 63(14):3883–3885
 40. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M (2015) mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. *Cancer Cell* 27(1):41–56. <https://doi.org/10.1016/j.ccell.2014.11.014>

41. Mueller JJ, Schlapp BA, Kumar R, Olvera N, Dao F, Abu-Rustum N, Aghajanian C, DeLair D, Hussein YR, Soslow RA, Levine DA, Weigelt B (2018) Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. *Gynecol Oncol* 150(1):127–135. <https://doi.org/10.1016/j.ygyno.2018.05.008>
42. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR (2018) Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. *Oncogene* 37(24):3183–3199. <https://doi.org/10.1038/s41388-018-0171-x>
43. McCormick F (2018) c-Raf in KRas mutant cancers: a moving target. *Cancer Cell* 33(2):158–159. <https://doi.org/10.1016/j.ccell.2018.01.017>
44. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Bohm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Kobel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileskin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringer KL (2019) The molecular origin and taxonomy of mucinous ovarian carcinoma. *Nat Commun* 10(1):3935. <https://doi.org/10.1038/s41467-019-11862-x>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.